img

Global Long-Acting Insulin Analogue Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Long-Acting Insulin Analogue Market Insights, Forecast to 2034

The global Long-Acting Insulin Analogue market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Long-Acting Insulin Analogue is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Long-Acting Insulin Analogue include Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals, The United Laboratories International Holdings and Tonghua Dongbao Pharmaceutical, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Long-Acting Insulin Analogue, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Long-Acting Insulin Analogue, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Long-Acting Insulin Analogue, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Long-Acting Insulin Analogue sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Long-Acting Insulin Analogue market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Long-Acting Insulin Analogue sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novo Nordisk, Sanofi, Eli Lilly and Company, Gan and Lee Pharmaceuticals, The United Laboratories International Holdings and Tonghua Dongbao Pharmaceutical, etc.



By Company


Novo Nordisk
Sanofi
Eli Lilly and Company
Gan and Lee Pharmaceuticals
The United Laboratories International Holdings
Tonghua Dongbao Pharmaceutical
Segment by Type
Insulin Glargine
Insulin Detemir
Insulin Degludec

Segment by Application


Type 2 Diabetes
Type 1 Diabetes
Gestational Diabetes
Other Diabetes

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Long-Acting Insulin Analogue in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Long-Acting Insulin Analogue manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-Acting Insulin Analogue sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Long-Acting Insulin Analogue Product Introduction
1.2 Market by Type
1.2.1 Global Long-Acting Insulin Analogue Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Insulin Glargine
1.2.3 Insulin Detemir
1.2.4 Insulin Degludec
1.3 Market by Application
1.3.1 Global Long-Acting Insulin Analogue Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Type 2 Diabetes
1.3.3 Type 1 Diabetes
1.3.4 Gestational Diabetes
1.3.5 Other Diabetes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Long-Acting Insulin Analogue Sales Estimates and Forecasts 2018-2034
2.2 Global Long-Acting Insulin Analogue Revenue by Region
2.2.1 Global Long-Acting Insulin Analogue Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Long-Acting Insulin Analogue Revenue by Region (2018-2024)
2.2.3 Global Long-Acting Insulin Analogue Revenue by Region (2024-2034)
2.2.4 Global Long-Acting Insulin Analogue Revenue Market Share by Region (2018-2034)
2.3 Global Long-Acting Insulin Analogue Sales Estimates and Forecasts 2018-2034
2.4 Global Long-Acting Insulin Analogue Sales by Region
2.4.1 Global Long-Acting Insulin Analogue Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Long-Acting Insulin Analogue Sales by Region (2018-2024)
2.4.3 Global Long-Acting Insulin Analogue Sales by Region (2024-2034)
2.4.4 Global Long-Acting Insulin Analogue Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Long-Acting Insulin Analogue Sales by Manufacturers
3.1.1 Global Long-Acting Insulin Analogue Sales by Manufacturers (2018-2024)
3.1.2 Global Long-Acting Insulin Analogue Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Long-Acting Insulin Analogue in 2022
3.2 Global Long-Acting Insulin Analogue Revenue by Manufacturers
3.2.1 Global Long-Acting Insulin Analogue Revenue by Manufacturers (2018-2024)
3.2.2 Global Long-Acting Insulin Analogue Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Long-Acting Insulin Analogue Revenue in 2022
3.3 Global Key Players of Long-Acting Insulin Analogue, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Long-Acting Insulin Analogue Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Long-Acting Insulin Analogue Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Long-Acting Insulin Analogue, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Long-Acting Insulin Analogue, Product Offered and Application
3.8 Global Key Manufacturers of Long-Acting Insulin Analogue, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Long-Acting Insulin Analogue Sales by Type
4.1.1 Global Long-Acting Insulin Analogue Historical Sales by Type (2018-2024)
4.1.2 Global Long-Acting Insulin Analogue Forecasted Sales by Type (2024-2034)
4.1.3 Global Long-Acting Insulin Analogue Sales Market Share by Type (2018-2034)
4.2 Global Long-Acting Insulin Analogue Revenue by Type
4.2.1 Global Long-Acting Insulin Analogue Historical Revenue by Type (2018-2024)
4.2.2 Global Long-Acting Insulin Analogue Forecasted Revenue by Type (2024-2034)
4.2.3 Global Long-Acting Insulin Analogue Revenue Market Share by Type (2018-2034)
4.3 Global Long-Acting Insulin Analogue Price by Type
4.3.1 Global Long-Acting Insulin Analogue Price by Type (2018-2024)
4.3.2 Global Long-Acting Insulin Analogue Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Long-Acting Insulin Analogue Sales by Application
5.1.1 Global Long-Acting Insulin Analogue Historical Sales by Application (2018-2024)
5.1.2 Global Long-Acting Insulin Analogue Forecasted Sales by Application (2024-2034)
5.1.3 Global Long-Acting Insulin Analogue Sales Market Share by Application (2018-2034)
5.2 Global Long-Acting Insulin Analogue Revenue by Application
5.2.1 Global Long-Acting Insulin Analogue Historical Revenue by Application (2018-2024)
5.2.2 Global Long-Acting Insulin Analogue Forecasted Revenue by Application (2024-2034)
5.2.3 Global Long-Acting Insulin Analogue Revenue Market Share by Application (2018-2034)
5.3 Global Long-Acting Insulin Analogue Price by Application
5.3.1 Global Long-Acting Insulin Analogue Price by Application (2018-2024)
5.3.2 Global Long-Acting Insulin Analogue Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Long-Acting Insulin Analogue Market Size by Type
6.1.1 US & Canada Long-Acting Insulin Analogue Sales by Type (2018-2034)
6.1.2 US & Canada Long-Acting Insulin Analogue Revenue by Type (2018-2034)
6.2 US & Canada Long-Acting Insulin Analogue Market Size by Application
6.2.1 US & Canada Long-Acting Insulin Analogue Sales by Application (2018-2034)
6.2.2 US & Canada Long-Acting Insulin Analogue Revenue by Application (2018-2034)
6.3 US & Canada Long-Acting Insulin Analogue Market Size by Country
6.3.1 US & Canada Long-Acting Insulin Analogue Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Long-Acting Insulin Analogue Sales by Country (2018-2034)
6.3.3 US & Canada Long-Acting Insulin Analogue Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Long-Acting Insulin Analogue Market Size by Type
7.1.1 Europe Long-Acting Insulin Analogue Sales by Type (2018-2034)
7.1.2 Europe Long-Acting Insulin Analogue Revenue by Type (2018-2034)
7.2 Europe Long-Acting Insulin Analogue Market Size by Application
7.2.1 Europe Long-Acting Insulin Analogue Sales by Application (2018-2034)
7.2.2 Europe Long-Acting Insulin Analogue Revenue by Application (2018-2034)
7.3 Europe Long-Acting Insulin Analogue Market Size by Country
7.3.1 Europe Long-Acting Insulin Analogue Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Long-Acting Insulin Analogue Sales by Country (2018-2034)
7.3.3 Europe Long-Acting Insulin Analogue Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Long-Acting Insulin Analogue Market Size
8.1.1 China Long-Acting Insulin Analogue Sales (2018-2034)
8.1.2 China Long-Acting Insulin Analogue Revenue (2018-2034)
8.2 China Long-Acting Insulin Analogue Market Size by Application
8.2.1 China Long-Acting Insulin Analogue Sales by Application (2018-2034)
8.2.2 China Long-Acting Insulin Analogue Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Long-Acting Insulin Analogue Market Size by Type
9.1.1 Asia Long-Acting Insulin Analogue Sales by Type (2018-2034)
9.1.2 Asia Long-Acting Insulin Analogue Revenue by Type (2018-2034)
9.2 Asia Long-Acting Insulin Analogue Market Size by Application
9.2.1 Asia Long-Acting Insulin Analogue Sales by Application (2018-2034)
9.2.2 Asia Long-Acting Insulin Analogue Revenue by Application (2018-2034)
9.3 Asia Long-Acting Insulin Analogue Sales by Region
9.3.1 Asia Long-Acting Insulin Analogue Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Long-Acting Insulin Analogue Revenue by Region (2018-2034)
9.3.3 Asia Long-Acting Insulin Analogue Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Long-Acting Insulin Analogue Market Size by Type
10.1.1 Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Long-Acting Insulin Analogue Market Size by Application
10.2.1 Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Country
10.3.1 Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Information
11.1.2 Novo Nordisk Overview
11.1.3 Novo Nordisk Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Novo Nordisk Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novo Nordisk Recent Developments
11.2 Sanofi
11.2.1 Sanofi Company Information
11.2.2 Sanofi Overview
11.2.3 Sanofi Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Sanofi Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi Recent Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Information
11.3.2 Eli Lilly and Company Overview
11.3.3 Eli Lilly and Company Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Eli Lilly and Company Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Eli Lilly and Company Recent Developments
11.4 Gan and Lee Pharmaceuticals
11.4.1 Gan and Lee Pharmaceuticals Company Information
11.4.2 Gan and Lee Pharmaceuticals Overview
11.4.3 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Gan and Lee Pharmaceuticals Recent Developments
11.5 The United Laboratories International Holdings
11.5.1 The United Laboratories International Holdings Company Information
11.5.2 The United Laboratories International Holdings Overview
11.5.3 The United Laboratories International Holdings Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 The United Laboratories International Holdings Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 The United Laboratories International Holdings Recent Developments
11.6 Tonghua Dongbao Pharmaceutical
11.6.1 Tonghua Dongbao Pharmaceutical Company Information
11.6.2 Tonghua Dongbao Pharmaceutical Overview
11.6.3 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Tonghua Dongbao Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Long-Acting Insulin Analogue Industry Chain Analysis
12.2 Long-Acting Insulin Analogue Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Long-Acting Insulin Analogue Production Mode & Process
12.4 Long-Acting Insulin Analogue Sales and Marketing
12.4.1 Long-Acting Insulin Analogue Sales Channels
12.4.2 Long-Acting Insulin Analogue Distributors
12.5 Long-Acting Insulin Analogue Customers
13 Market Dynamics
13.1 Long-Acting Insulin Analogue Industry Trends
13.2 Long-Acting Insulin Analogue Market Drivers
13.3 Long-Acting Insulin Analogue Market Challenges
13.4 Long-Acting Insulin Analogue Market Restraints
14 Key Findings in The Global Long-Acting Insulin Analogue Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Long-Acting Insulin Analogue Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Insulin Glargine
Table 3. Major Manufacturers of Insulin Detemir
Table 4. Major Manufacturers of Insulin Degludec
Table 5. Global Long-Acting Insulin Analogue Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Long-Acting Insulin Analogue Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Long-Acting Insulin Analogue Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Long-Acting Insulin Analogue Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Long-Acting Insulin Analogue Revenue Market Share by Region (2018-2024)
Table 10. Global Long-Acting Insulin Analogue Revenue Market Share by Region (2024-2034)
Table 11. Global Long-Acting Insulin Analogue Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 12. Global Long-Acting Insulin Analogue Sales by Region (2018-2024) & (K Units)
Table 13. Global Long-Acting Insulin Analogue Sales by Region (2024-2034) & (K Units)
Table 14. Global Long-Acting Insulin Analogue Sales Market Share by Region (2018-2024)
Table 15. Global Long-Acting Insulin Analogue Sales Market Share by Region (2024-2034)
Table 16. Global Long-Acting Insulin Analogue Sales by Manufacturers (2018-2024) & (K Units)
Table 17. Global Long-Acting Insulin Analogue Sales Share by Manufacturers (2018-2024)
Table 18. Global Long-Acting Insulin Analogue Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Long-Acting Insulin Analogue Revenue Share by Manufacturers (2018-2024)
Table 20. Global Key Players of Long-Acting Insulin Analogue, Industry Ranking, 2021 VS 2022 VS 2024
Table 21. Long-Acting Insulin Analogue Price by Manufacturers 2018-2024 (US$/Unit)
Table 22. Global Long-Acting Insulin Analogue Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Long-Acting Insulin Analogue by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-Acting Insulin Analogue as of 2022)
Table 24. Global Key Manufacturers of Long-Acting Insulin Analogue, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Long-Acting Insulin Analogue, Product Offered and Application
Table 26. Global Key Manufacturers of Long-Acting Insulin Analogue, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Long-Acting Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 29. Global Long-Acting Insulin Analogue Sales by Type (2024-2034) & (K Units)
Table 30. Global Long-Acting Insulin Analogue Sales Share by Type (2018-2024)
Table 31. Global Long-Acting Insulin Analogue Sales Share by Type (2024-2034)
Table 32. Global Long-Acting Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Long-Acting Insulin Analogue Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Long-Acting Insulin Analogue Revenue Share by Type (2018-2024)
Table 35. Global Long-Acting Insulin Analogue Revenue Share by Type (2024-2034)
Table 36. Long-Acting Insulin Analogue Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Long-Acting Insulin Analogue Price Forecast by Type (2024-2034) & (US$/Unit)
Table 38. Global Long-Acting Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 39. Global Long-Acting Insulin Analogue Sales by Application (2024-2034) & (K Units)
Table 40. Global Long-Acting Insulin Analogue Sales Share by Application (2018-2024)
Table 41. Global Long-Acting Insulin Analogue Sales Share by Application (2024-2034)
Table 42. Global Long-Acting Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Long-Acting Insulin Analogue Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Long-Acting Insulin Analogue Revenue Share by Application (2018-2024)
Table 45. Global Long-Acting Insulin Analogue Revenue Share by Application (2024-2034)
Table 46. Long-Acting Insulin Analogue Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Long-Acting Insulin Analogue Price Forecast by Application (2024-2034) & (US$/Unit)
Table 48. US & Canada Long-Acting Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 49. US & Canada Long-Acting Insulin Analogue Sales by Type (2024-2034) & (K Units)
Table 50. US & Canada Long-Acting Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 51. US & Canada Long-Acting Insulin Analogue Revenue by Type (2024-2034) & (US$ Million)
Table 52. US & Canada Long-Acting Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 53. US & Canada Long-Acting Insulin Analogue Sales by Application (2024-2034) & (K Units)
Table 54. US & Canada Long-Acting Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 55. US & Canada Long-Acting Insulin Analogue Revenue by Application (2024-2034) & (US$ Million)
Table 56. US & Canada Long-Acting Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 57. US & Canada Long-Acting Insulin Analogue Revenue by Country (2018-2024) & (US$ Million)
Table 58. US & Canada Long-Acting Insulin Analogue Revenue by Country (2024-2034) & (US$ Million)
Table 59. US & Canada Long-Acting Insulin Analogue Sales by Country (2018-2024) & (K Units)
Table 60. US & Canada Long-Acting Insulin Analogue Sales by Country (2024-2034) & (K Units)
Table 61. Europe Long-Acting Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 62. Europe Long-Acting Insulin Analogue Sales by Type (2024-2034) & (K Units)
Table 63. Europe Long-Acting Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 64. Europe Long-Acting Insulin Analogue Revenue by Type (2024-2034) & (US$ Million)
Table 65. Europe Long-Acting Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 66. Europe Long-Acting Insulin Analogue Sales by Application (2024-2034) & (K Units)
Table 67. Europe Long-Acting Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 68. Europe Long-Acting Insulin Analogue Revenue by Application (2024-2034) & (US$ Million)
Table 69. Europe Long-Acting Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 70. Europe Long-Acting Insulin Analogue Revenue by Country (2018-2024) & (US$ Million)
Table 71. Europe Long-Acting Insulin Analogue Revenue by Country (2024-2034) & (US$ Million)
Table 72. Europe Long-Acting Insulin Analogue Sales by Country (2018-2024) & (K Units)
Table 73. Europe Long-Acting Insulin Analogue Sales by Country (2024-2034) & (K Units)
Table 74. China Long-Acting Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 75. China Long-Acting Insulin Analogue Sales by Type (2024-2034) & (K Units)
Table 76. China Long-Acting Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 77. China Long-Acting Insulin Analogue Revenue by Type (2024-2034) & (US$ Million)
Table 78. China Long-Acting Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 79. China Long-Acting Insulin Analogue Sales by Application (2024-2034) & (K Units)
Table 80. China Long-Acting Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 81. China Long-Acting Insulin Analogue Revenue by Application (2024-2034) & (US$ Million)
Table 82. Asia Long-Acting Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 83. Asia Long-Acting Insulin Analogue Sales by Type (2024-2034) & (K Units)
Table 84. Asia Long-Acting Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 85. Asia Long-Acting Insulin Analogue Revenue by Type (2024-2034) & (US$ Million)
Table 86. Asia Long-Acting Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 87. Asia Long-Acting Insulin Analogue Sales by Application (2024-2034) & (K Units)
Table 88. Asia Long-Acting Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 89. Asia Long-Acting Insulin Analogue Revenue by Application (2024-2034) & (US$ Million)
Table 90. Asia Long-Acting Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 91. Asia Long-Acting Insulin Analogue Revenue by Region (2018-2024) & (US$ Million)
Table 92. Asia Long-Acting Insulin Analogue Revenue by Region (2024-2034) & (US$ Million)
Table 93. Asia Long-Acting Insulin Analogue Sales by Region (2018-2024) & (K Units)
Table 94. Asia Long-Acting Insulin Analogue Sales by Region (2024-2034) & (K Units)
Table 95. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 96. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Type (2024-2034) & (K Units)
Table 97. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 98. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Type (2024-2034) & (US$ Million)
Table 99. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 100. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Application (2024-2034) & (K Units)
Table 101. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 102. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Application (2024-2034) & (US$ Million)
Table 103. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 104. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Country (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue by Country (2024-2034) & (US$ Million)
Table 106. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Country (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales by Country (2024-2034) & (K Units)
Table 108. Novo Nordisk Company Information
Table 109. Novo Nordisk Description and Major Businesses
Table 110. Novo Nordisk Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Novo Nordisk Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Novo Nordisk Recent Developments
Table 113. Sanofi Company Information
Table 114. Sanofi Description and Major Businesses
Table 115. Sanofi Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. Sanofi Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Sanofi Recent Developments
Table 118. Eli Lilly and Company Company Information
Table 119. Eli Lilly and Company Description and Major Businesses
Table 120. Eli Lilly and Company Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Eli Lilly and Company Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Eli Lilly and Company Recent Developments
Table 123. Gan and Lee Pharmaceuticals Company Information
Table 124. Gan and Lee Pharmaceuticals Description and Major Businesses
Table 125. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Gan and Lee Pharmaceuticals Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Gan and Lee Pharmaceuticals Recent Developments
Table 128. The United Laboratories International Holdings Company Information
Table 129. The United Laboratories International Holdings Description and Major Businesses
Table 130. The United Laboratories International Holdings Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. The United Laboratories International Holdings Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. The United Laboratories International Holdings Recent Developments
Table 133. Tonghua Dongbao Pharmaceutical Company Information
Table 134. Tonghua Dongbao Pharmaceutical Description and Major Businesses
Table 135. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Tonghua Dongbao Pharmaceutical Long-Acting Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Tonghua Dongbao Pharmaceutical Recent Developments
Table 138. Key Raw Materials Lists
Table 139. Raw Materials Key Suppliers Lists
Table 140. Long-Acting Insulin Analogue Distributors List
Table 141. Long-Acting Insulin Analogue Customers List
Table 142. Long-Acting Insulin Analogue Market Trends
Table 143. Long-Acting Insulin Analogue Market Drivers
Table 144. Long-Acting Insulin Analogue Market Challenges
Table 145. Long-Acting Insulin Analogue Market Restraints
Table 146. Research Programs/Design for This Report
Table 147. Key Data Information from Secondary Sources
Table 148. Key Data Information from Primary Sources
List of Figures
Figure 1. Long-Acting Insulin Analogue Product Picture
Figure 2. Global Long-Acting Insulin Analogue Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Long-Acting Insulin Analogue Market Share by Type in 2022 & 2034
Figure 4. Insulin Glargine Product Picture
Figure 5. Insulin Detemir Product Picture
Figure 6. Insulin Degludec Product Picture
Figure 7. Global Long-Acting Insulin Analogue Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Long-Acting Insulin Analogue Market Share by Application in 2022 & 2034
Figure 9. Type 2 Diabetes
Figure 10. Type 1 Diabetes
Figure 11. Gestational Diabetes
Figure 12. Other Diabetes
Figure 13. Long-Acting Insulin Analogue Report Years Considered
Figure 14. Global Long-Acting Insulin Analogue Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Long-Acting Insulin Analogue Revenue 2018-2034 (US$ Million)
Figure 16. Global Long-Acting Insulin Analogue Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Long-Acting Insulin Analogue Revenue Market Share by Region (2018-2034)
Figure 18. Global Long-Acting Insulin Analogue Sales 2018-2034 ((K Units)
Figure 19. Global Long-Acting Insulin Analogue Sales Market Share by Region (2018-2034)
Figure 20. US & Canada Long-Acting Insulin Analogue Sales YoY (2018-2034) & (K Units)
Figure 21. US & Canada Long-Acting Insulin Analogue Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Long-Acting Insulin Analogue Sales YoY (2018-2034) & (K Units)
Figure 23. Europe Long-Acting Insulin Analogue Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Long-Acting Insulin Analogue Sales YoY (2018-2034) & (K Units)
Figure 25. China Long-Acting Insulin Analogue Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Asia (excluding China) Long-Acting Insulin Analogue Sales YoY (2018-2034) & (K Units)
Figure 27. Asia (excluding China) Long-Acting Insulin Analogue Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Long-Acting Insulin Analogue Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Long-Acting Insulin Analogue in the World: Market Share by Long-Acting Insulin Analogue Revenue in 2022
Figure 32. Global Long-Acting Insulin Analogue Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Long-Acting Insulin Analogue Sales Market Share by Type (2018-2034)
Figure 34. Global Long-Acting Insulin Analogue Revenue Market Share by Type (2018-2034)
Figure 35. Global Long-Acting Insulin Analogue Sales Market Share by Application (2018-2034)
Figure 36. Global Long-Acting Insulin Analogue Revenue Market Share by Application (2018-2034)
Figure 37. US & Canada Long-Acting Insulin Analogue Sales Market Share by Type (2018-2034)
Figure 38. US & Canada Long-Acting Insulin Analogue Revenue Market Share by Type (2018-2034)
Figure 39. US & Canada Long-Acting Insulin Analogue Sales Market Share by Application (2018-2034)
Figure 40. US & Canada Long-Acting Insulin Analogue Revenue Market Share by Application (2018-2034)
Figure 41. US & Canada Long-Acting Insulin Analogue Revenue Share by Country (2018-2034)
Figure 42. US & Canada Long-Acting Insulin Analogue Sales Share by Country (2018-2034)
Figure 43. U.S. Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Long-Acting Insulin Analogue Sales Market Share by Type (2018-2034)
Figure 46. Europe Long-Acting Insulin Analogue Revenue Market Share by Type (2018-2034)
Figure 47. Europe Long-Acting Insulin Analogue Sales Market Share by Application (2018-2034)
Figure 48. Europe Long-Acting Insulin Analogue Revenue Market Share by Application (2018-2034)
Figure 49. Europe Long-Acting Insulin Analogue Revenue Share by Country (2018-2034)
Figure 50. Europe Long-Acting Insulin Analogue Sales Share by Country (2018-2034)
Figure 51. Germany Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 52. France Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 53. U.K. Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 54. Italy Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 55. Russia Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 56. China Long-Acting Insulin Analogue Sales Market Share by Type (2018-2034)
Figure 57. China Long-Acting Insulin Analogue Revenue Market Share by Type (2018-2034)
Figure 58. China Long-Acting Insulin Analogue Sales Market Share by Application (2018-2034)
Figure 59. China Long-Acting Insulin Analogue Revenue Market Share by Application (2018-2034)
Figure 60. Asia Long-Acting Insulin Analogue Sales Market Share by Type (2018-2034)
Figure 61. Asia Long-Acting Insulin Analogue Revenue Market Share by Type (2018-2034)
Figure 62. Asia Long-Acting Insulin Analogue Sales Market Share by Application (2018-2034)
Figure 63. Asia Long-Acting Insulin Analogue Revenue Market Share by Application (2018-2034)
Figure 64. Asia Long-Acting Insulin Analogue Revenue Share by Region (2018-2034)
Figure 65. Asia Long-Acting Insulin Analogue Sales Share by Region (2018-2034)
Figure 66. Japan Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 67. South Korea Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 68. China Taiwan Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 69. Southeast Asia Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 70. India Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue Market Share by Type (2018-2034)
Figure 73. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue Market Share by Application (2018-2034)
Figure 75. Middle East, Africa and Latin America Long-Acting Insulin Analogue Revenue Share by Country (2018-2034)
Figure 76. Middle East, Africa and Latin America Long-Acting Insulin Analogue Sales Share by Country (2018-2034)
Figure 77. Brazil Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 78. Mexico Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 79. Turkey Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 80. Israel Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 81. GCC Countries Long-Acting Insulin Analogue Revenue (2018-2034) & (US$ Million)
Figure 82. Long-Acting Insulin Analogue Value Chain
Figure 83. Long-Acting Insulin Analogue Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries